Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "credit fc26 Visitez le site Buyfc26coins.com La référence incontestée pour les FC 26 coins.VIiF"

Looking for quality documents?
news icon
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns
news icon
Repligen Appoints Jason K. Garland as Chief Financial Officer
publications icon
Ultrafiltration Behavior of Partially Retained Proteins and Completely Retained Proteins Using Equally-Staged Single Pass Tangential Flow Filtration Membranes Publication
publications icon
Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals
external link icon
Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines
WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced that they have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin to be utilized in the purification of COVID-19 vaccines.
The availability of this COVID-19 affinity resin is the result of an accelerated program to provide COVID-19 vaccine manufacturers with a high purity capture step, decreasing processing time and significantly improving overall yield in the production of these critical vaccines. Working closely with Navigo Proteins on the ligand development and partnering with Purolite Life Sciences on Praesto ® agarose bead technology, the resulting product meets all the
publications icon
Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing
By Michelle Yen Tran and Amine A. Kamen Frontiers
external link icon
Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting
external link icon
Repligen Receives FDA Approval to Initiate Phase 1 Clinical Trial of Potential Treatment for Spinal Muscular Atrophy
external link icon
Repligen to Present at the Lazard Capital Markets 7th Annual Healthcare Conference Wednesday, November 17th, 2:45 p.m. EST
external link icon
Repligen Reports Notice of Allowance of United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support